[ET Net News Agency, 2 September 2019] Credit Suisse lowered its target price for
Shanghai Pharmaceuticals Holding (02607) to HK$16.18 from HK$18.14 and maintained its
"neutral" rating.
The research house said the company's 1H revenue and net profit account for 52.7% and
49.9% of its FY2019 estimates. It has guided that in the next three years, R&D cost per
manufacturing will increase to 7-10%, each year rising by 1%. 1H's pharma manufacturing
grew 24% to Rmb11,942mn.
Credit Suisse expects its growth to decline by 10% within the next three years. It
lowered its 2020/21 net profit by 2.70%/5.54% due to increasing investment in R&D as
indicated by management. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02607 SH PHARMA
Nominal 
10.780 +0.080 (+0.748%) Others
02/09/2019 13:55
{I-bank focus}CS cuts Shanghai Pharma (02607) to HK$16.18
| Remark: | Real time quote last updated: 18/04/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |